Evidence map›Paper›PMID 31598677›Full record

ArticleNucleic acids research2019

A nuclease-polymerase chain reaction enables amplification of probes used for capture-based DNA target enrichment.

Ka Wai Leong, Fangyan Yu, Viktor A Adalsteinsson, Sarah Reed, Gregory Gydush, Ioannis Ladas, Jiang Li, Kelan G Tantisira, Gerassimos Mike Makrigiorgos

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Programmable High-Speed and Hyper-Efficiency DNA Signal Magnifier.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ka Wai LeongDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Fangyan YuDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Viktor A AdalsteinssonThe Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sarah ReedThe Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gregory GydushThe Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ioannis LadasDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jiang LiThe Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medicine School, Boston, MA 02142, USA.
Kelan G TantisiraThe Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medicine School, Boston, MA 02142, USA.
Gerassimos Mike MakrigiorgosDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Brigham and Women's Hospital · USBroad Institute · USDana-Farber Cancer Institute · USDana-Farber Brigham Cancer Center · US

Funding

Comprehensive minimal residual disease tracking in cancerR01CA221874 · NCI · DANA-FARBER CANCER INST · PI Viktor Adalsteinsson, G. Mike Makrigiorgos · 2018 to 2026
$2.5M
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)R01HL129935 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2017
$1.4M
Maximum efficiency sequencing using nuclease-based mutation enrichment and digital barcodesR33CA217652 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2017 to 2019
$1.3M
NCI NIH HHS R01 CA221874NCI NIH HHS R33 CA217652NHLBI NIH HHS R01 HL129935
6 · The paper itself

Abstract

DNA target enrichment via hybridization capture is a commonly adopted approach which remains expensive due in-part to using biotinylated-probe panels. Here we provide a novel isothermal amplification reaction to amplify rapidly existing probe panels without knowledge of the sequences involved, thereby decreasing a major portion of the overall sample preparation cost. The reaction employs two thermostable enzymes, BST-polymerase and duplex-specific nuclease DSN. DSN initiates random 'nicks' on double-stranded-DNA which enable BST to polymerize DNA by displacing the nicked-strand. Displaced strands re-hybridize and the process leads to an exponential chain-reaction generating biotinylated DNA fragments within minutes. When starting from single-stranded-DNA, DNA is first converted to double-stranded-DNA via terminal-deoxynucleotidyl-transferase (TdT) prior to initiation of BST-DSN reaction. Biotinylated probes generated by TdT-BST-DSN (TBD) reactions using panels of 33, 190 or 7186 DNA targets are used for hybrid-capture-based target enrichment from amplified circulating-DNA, followed by targeted re-sequencing. Polymerase-nuclease isothermal-chain-reactions generate random amplified probes with no apparent sequence dependence. One round of target-capture using TBD probes generates a modest on-target sequencing ratio, while two successive rounds of capture generate >80% on-target reads with good sequencing uniformity. TBD-reactions generate enough capture-probes to increase by approximately two to three orders-of-magnitude the target-enrichment experiments possible from an initial set of probes.

Indexed as

BiotinylationCell-Free Nucleic AcidsDNADNA ProbesHealthy VolunteersHumansMolecular Diagnostic TechniquesNeoplasmsNucleic Acid Amplification TechniquesOligonucleotide ProbesPolymerase Chain ReactionCell-Free Nucleic AcidsDNADNA ProbesOligonucleotide Probes

Identifiers

PMID31598677
PMCPMC6902007
OpenAlexW2980245990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.